Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Guggenheim Adjusts Price Target on Incyte to $86 From $92
Wolfe Research Initiates Incyte(INCY.US) With Buy Rating, Announces Target Price $84
Optimism Around Aquestive As It Moves Forward With Severe Allergy, Baldness Candidate
Is Incyte Stock Underperforming the Nasdaq?
Truist Financial Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $74
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Incyte Corporation's (NASDAQ:INCY) Business And Shares Still Trailing The Industry
Incyte To Present At Cantor Global Healthcare Conference; Webcast At 9:45 AM ET
Express News | Incyte Corporation : Deutsche Bank Raises Target Price to $61 From $60
Incyte, Syndax Report Publication Of Data From Pivotal AGAVE-201 Trial Of Niktimvo; Trial Met The Primary Endpoint Across All Cohorts
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Incyte Downgraded at Truist on Jakafi Patent Cliff
Update: Truist Securities Downgrades Incyte to Hold From Buy, Cuts Price Target to $74 From $83
Truist Financial Downgrades Incyte(INCY.US) to Hold Rating, Announces Target Price $74
Truist Financial analyst Srikripa Devarakonda downgrades $Incyte(INCY.US)$ to a hold rating, and sets the target price at $74.According to TipRanks data, the analyst has a success rate of 57.4% and
Express News | Incyte : Truist Securities Cuts to Hold From Buy; Cuts Target Price to $74 From $83
Incyte's Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics
Incyte Closes 5% Higher Bolstered by Zynyz Data, Guggenheim Note
Incyte Insider Sold Shares Worth $526,948, According to a Recent SEC Filing